• News
  • SAN DIEGO
  • Finance

Halozyme climbs as analyst upgrades stock

Shares of Halozyme Therapeutics Inc. jumped Monday after a BMO Capital Markets analyst upgraded the stock, saying he expects it to do better in 2013.

Analyst Jim Birchenough upgraded the stock to “Outperform” from “Market Perform” and tripled his price target on the stock to $12. Birchenough noted that Halozyme shares struggled in 2012, but he thinks European Union regulators will issue a favorable opinion about the company's version of the cancer drug Herceptin during the first quarter. Later in the year, clinical trial data for other products could raise the company's stock price.

San Diego-based Halozyme's Enhanze technology is designed to temporarily break down a substance in the body that forms a barrier between cells so drugs can be absorbed faster. That would allow some drugs to be delivered by an injection instead of an IV drip.

Several companies are testing use of the company's recombinant hyaluronidase enzyme, including Roche and Pfizer (NYSE: PFE), the world's biggest drug company.

Roche is testing the company's recombinant hyaluronidase enzyme along with several drugs, including the cancer drugs Herceptin and MabThera.

Halozyme (Nasdaq: HALO) could get more than $500 million from the Pfizer deal.

The company's stock took a battering in August, when the FDA temporarily stopped several studies that involved Halozyme's enzyme rHuPH20. The agency was concerned about possible side effects on fertility, reproduction and fetal development from antibodies produced in response to the enzyme.

Halozyme is working to resume some studies.

Halozyme shares rose $1.13, or 15.6 percent, to close Monday at $8.34.

The stock lost half its value on Aug. 2, closing at $4.30, when the FDA announced the hold on the enzyme studies. News of the Pfizer deal on Dec. 21 helped shares recover.

RELATED ARTICLES:

Halozyme gains on $4 million payment by Roche

Halozyme leases more space in Sorrento Valley

Websense shares get a boost from new CEO, billings

Leap gains as analyst says chance of MetroPCS, T-Mobile deal

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Subscribe Today!